香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） 本公司及銀諾技術各自認購寧波銀行結構性存款產品透過市場進行，代價以本集 團自有資金支付（為免生疑問，上述資金不涉及本公司因上市而募集的任何所得 款項）。 於本公司及銀諾技術各自認購寧波銀行結構性存款產品前，由於本公司及銀諾技 術於2025年10月14日各自認購的結構性存款產品已於2025年10月30日到期（詳情 請參閱本公司日期為2025年10月14日的公告），概無本集團已認購處於存續期的 寧波銀行金融產品。 （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年11月3日，本公司及銀諾技術（本公司一間直接全資附屬公 司）以代價合共人民幣105,000,000元（即其總本金額）向寧波銀行認購一款結構性 存款產 ...

Core Viewpoint - Silver诺医药-B (02591) announced the subscription of a structured deposit product from Ningbo Bank for a total consideration of RMB 105 million, which equals its total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, is engaging in a financial investment through a structured deposit [1] - The total investment amount is RMB 105 million, indicating a significant commitment to this financial product [1]

Core Viewpoint - Silver诺医药-B (02591.HK) announced a subscription to a structured deposit product from Ningbo Bank for a total cost of RMB 105 million, which represents the total principal amount [1] Group 1 - The company will subscribe to a bank structured deposit product with Ningbo Bank [1] - The total investment amount is RMB 105 million, equivalent to its total principal amount [1]

Core Viewpoint - Silver诺医药-B (02591) announced the subscription of a structured deposit product from Ningbo Bank for a total amount of RMB 105 million, which is equivalent to its total principal amount [1] Group 1 - The company, along with its wholly-owned subsidiary Silver诺技术, will invest in the structured deposit product [1] - The transaction is set to take place on October 14, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 有關認購結構性存款產品的須予披露交易 董事會宣佈，於2025年10月14日，本公司及銀諾技術（本公司一間直接全資附屬 公司）以代價合共人民幣105,000,000元（即其總本金額）向寧波銀行認購一項銀行 結構性存款產品。 本公司及銀諾技術各自認購寧波銀行結構性存款產品的主要條款載列如下： | 認購方 | 產品名稱 | 本金額 | 認購日期 生效日期 | 到期日 | 預期年化回報率 | | --- | --- | --- | --- | --- | --- | | 本公司 | 寧波銀行結構性 | 人民幣 | 2025年10月14日 2025年10月16日 | 2025年10月30日 | 介乎0.5% | | | 存款產 ...

Summary of Key Points Core Viewpoint - As of October 14, a total of 75 stocks reached their 52-week highs, with notable performances from Lihua Securities Holdings (08350), Deutsche Bank Tianxia (02418), and Chuangsheng Holdings (02680) [1]. 52-Week Highs - Lihua Securities Holdings (08350) achieved a closing price of 0.325, with a peak of 0.390, marking a high rate of 34.48% - Deutsche Bank Tianxia (02418) closed at 8.120, reaching a maximum of 8.990, with a high rate of 24.86% - Chuangsheng Holdings (02680) closed at 12.100, peaking at 12.350, with a high rate of 23.50% - Other notable stocks include Century United Holdings (01959) with a high rate of 20.97% and Silicon Xin Group (08349) with 14.38% [1]. 52-Week Lows - Hengda Group Holdings (03616) recorded a closing price of 0.345, with a low of 0.300, reflecting a decline rate of -11.76% - China Technology Industry Group (08111) reached a low of 0.085, with a decline rate of -8.89% - Other significant declines include Golden Leaf International Group (08549) at -8.06% and Changfeng Pharmaceutical (02652) at -4.90% [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 廣州銀諾醫藥集團股份有限公司（於中華人民共和國成立的股份有限公司） 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02591 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 420,285,370 | RMB | | 1 RMB | | 420,285,370 | | 2. 股份分類 | ...

Core Viewpoint - The company has initiated the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions in China, with plans to recruit approximately 800 participants by September 30, 2025 [1] Company Summary - The company is focused on developing Isuparaglutide α as a treatment for obesity and overweight [1] - The Phase III clinical trial represents a significant step in the product's development pipeline [1] Industry Summary - The clinical trial is part of a broader trend in the pharmaceutical industry towards addressing obesity and related health issues [1] - The recruitment of 800 participants indicates a robust approach to validating the efficacy and safety of the treatment [1]

Core Insights - The company, Silver诺医药-B (02591), has announced the initiation of the first patient dosing in a Phase III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight conditions [1] Company Developments - The clinical trial is set to recruit approximately 800 participants in China [1]

Core Insights - The company, Silver诺医药-B (02591.HK), has initiated a Phase IIb/III clinical trial for its core product, Isuparaglutide α, aimed at treating obesity and overweight in China, set to start in March 2025 [1] - As of September 30, 2025, the company has administered the first dose to a patient in the Phase III clinical trial for the treatment of obesity and overweight in China [1] - The company plans to recruit approximately 800 participants for this clinical trial [1]